Study outcomes for hepatitis B with “indeterminate” disease phase
Part of Cancer, Digestive system, Infections clinical trials.
This trial studies what happens to people with hepatitis B who have hepatitis B surface antigen for more than 6 months, are “HBeAg-negative,” and have certain blood and liver-scarring levels despite normal or near-normal liver inflammation. It may help doctors understand the best care for this specific group before clear treatment phases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have hepatitis B: HBsAg positive for more than 6 months.
- You have HBeAg negative and anti-HBe positive blood tests.
- Your HBV DNA is above 2,000 IU/mL (a blood measure of virus levels).
- Your liver inflammation is low and liver scarring is limited (or liver stiffness is high).
- You have not started hepatitis B treatment before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at long-term outcomes in people with chronic hepatitis B who take antiviral medicines or receive interferon. It may help doctors understand which treatments work best over time and who is most likely to benefit.
This trial is for people with chronic hepatitis B who have already cleared the virus with interferon treatment. It tests ongoing strategies to help maintain their health and prevent the virus from coming back.
This trial tests an experimental vaccine therapy to help control or possibly cure chronic hepatitis B. It is designed to see whether the treatment is safe and how well it affects the hepatitis B virus in adults.
This study collects a small sample of liver cells to understand how hepatitis B virus behaves in the liver and how the immune system responds. This could help improve future treatments for chronic hepatitis B.
This Phase 2 trial studies an injection (HRS-5635), either alone or with other medicines, to see if it is safe and helps keep chronic hepatitis B under control. It is for people who are already on standard hepatitis B antivirals and have low or undetectable viral levels.
This study looks at a new way to detect the hepatitis B virus in the blood, even after standard tests say it's gone. It may help people who have stopped treatment and want to see if the virus comes back.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.